Compare Amgen, Inc. (AMGN) vs Invesco Solar ETF (TAN) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Amgen, Inc. vs Invesco Solar ETF — how do they compare? Amgen, Inc. trades at $363.66 (market cap $196.12B), while Invesco Solar ETF trades at $54.84. The key difference: Amgen, Inc. pays a 2.77% dividend while Invesco Solar ETF pays none, and Amgen, Inc. is trading nearer its 52-week high, Invesco Solar ETF nearer its low. Which is the better fit depends on your goals.
| AMGN | TAN | |
|---|---|---|
Market Cap | $196.12B | — |
Sector | Health | Sector/Thematic |
52-Week High | $388.16 | $73.95 |
52-Week Low | $271.18 | $36.07 |
Enterprise Value | $241.41B | — |
Dividend Yield | 2.77% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AMGN trades at $363.39, down slightly by 0.06% today, with a bullish technical signal from moving averages. The company reported strong Q1 2026 earnings, beating estimates with EPS of $5.15 versus $4.77 expected. Revenue grew to $36.75B in 2025, with a net income margin of 20.96%. Recent news includes a favorable court ruling blocking a price cap on Enbrel in Colorado, but regulatory challenges persist for Tavneos in Europe.
The outlook remains positive due to consistent earnings beats and a diversified product portfolio, though risks include regulatory setbacks and competitive pressures. Analyst consensus is bullish with a 57.9% buy rating and a price target of $357.38, slightly below the current price, indicating potential for stability with upside from pipeline developments.
TAN (Invesco Solar ETF) trades at $54.96, showing minimal daily movement with a 0.02% gain. The technical picture appears bearish with moving averages signaling selling pressure, though oscillators remain neutral. Recent news highlights both opportunities from AI-driven electricity demand and headwinds from regulatory challenges and supply chain costs. The ETF has transformed into a focused utility-scale solar play, benefiting from global clean energy investments while facing valuation concerns.
The outlook for TAN balances long-term growth potential from energy transition trends against near-term volatility. Investment opportunity lies in exposure to solar infrastructure benefiting from AI power demands, though risks include political uncertainty, Chinese supply chain tensions, and competitive pressure from nuclear energy. Current technical weakness suggests cautious entry points may be preferable for long-term investors.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Amgen, Inc.
Amgen is a leader in biotechnology-based human therapeutics, with historical expertise in renal disease and cancer supportive-care products. Flagship drugs include red blood cell boosters Epogen and Aranesp, immune system boosters Neupogen and Neulasta, and Enbrel and Otezla for inflammatory diseases. Amgen introduced its first cancer therapeutic, Vectibix, in 2006 and markets bone-strengthening drug Prolia/Xgeva (approved 2010) and Evenity (2019). The acquisition of Onyx bolstered the firm's therapeutic oncology portfolio with Kyprolis. Recent launches include Repatha (cholesterol-lowering), Aimovig (migraine), Lumakras (lung cancer), and Tezspire (asthma). Amgen's biosimilar portfolio includes Mvasi (biosimilar Avastin), Kanjinti (biosimilar Herceptin), and Amgevita (biosimilar Humira).
Read more on AMGN →About Invesco Solar ETF
TAN is a thematic ETF that tracks the MAC Global Solar Energy Index. It provides targeted exposure to the global solar industry, including manufacturers of solar panels, installers, and component suppliers like Enphase and First Solar.
Read more on TAN →
